Compare VATE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VATE | KLRS |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 92.8M |
| IPO Year | 1996 | 2020 |
| Metric | VATE | KLRS |
|---|---|---|
| Price | $7.68 | $3.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 93.8K | 52.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,246,000,000.00 | $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $3.03 |
| 52 Week High | $21.30 | $11.88 |
| Indicator | VATE | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | N/A |
| Support Level | $6.48 | N/A |
| Resistance Level | $8.20 | N/A |
| Average True Range (ATR) | 0.48 | 0.00 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 88.28 | 0.00 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.